Every 10-Q that BiomX Inc. (PHGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PHGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHGE filings page.
BiomX Inc. (PHGE) reports a major strategic and financial transformation for the quarter ended June 30, 2026, shifting from phage-based drug development to defense, security and critical infrastructure technology. It completed business acquisitions of ZorroNet and a 60% stake in DFSL, adding $25.4 million of goodwill and other intangibles and creating $6.8 million of non‑controlling interests. Total assets rose to $28.2 million from $5.8 million at December 31, 2025, and stockholders’ equity moved from a deficit of $(1.3) million to positive equity of $17.6 million, driven largely by these transactions and warrant-related equity issuances.
Operations remain highly loss‑making and cash‑constrained. Revenue for the first half of 2026 was $0.3 million, while net loss was $23.0 million, including large non‑cash charges from warrant and derivative remeasurement and a $5.2 million day‑one loss on a financing transaction, partly offset by a $1.9 million gain from deconsolidating insolvent BiomX Israel. Operating cash outflow was $6.6 million and period‑end cash and cash equivalents were only $0.3 million. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern absent additional financing, and plans to rely on equity/debt raises, an at‑the‑market program, and new revenue from DFSL and ZorroNet.
BiomX Inc. reported Q1 2026 results reflecting a deep strategic shift and severe financial strain. The company is transitioning from biopharma to defense, security and critical‑infrastructure technologies through new subsidiaries DFSL, Zorronet and X Security, whose results are not yet in these statements.
For the quarter, BiomX posted a net loss of $19.1 million and an operating loss of $1.3 million, compared with a $7.8 million operating loss a year earlier. Large non‑cash charges tied to January 2026 Series Y preferred stock and warrant financing, including a $5.2 million day‑one loss and $14.1 million loss from fair‑value changes in derivatives, drove the result.
Cash and cash equivalents were $1.2 million as of March 31, 2026, versus $5.0 million at year‑end 2025, with total assets of $3.3 million and an accumulated deficit of $236.0 million. Management states there is “substantial doubt” about the company’s ability to continue as a going concern and expects existing funds plus anticipated subsidiary revenues will cover operations only for the next several months.
Subsequent to quarter‑end, BiomX acquired 100% of Zorronet and 60% of DFSL and secured a related credit line with Mandragola. The company also received a NYSE American notice for failing stockholders’ equity listing standards and has submitted a remediation plan, with potential delisting if compliance is not restored.
BiomX (PHGE) reported Q3 2025 results marked by ongoing R&D progress alongside tight liquidity. The company posted a net loss of $9.166M and an operating loss of $8.536M. R&D expenses, net, were $6.122M (down 16% year over year), and G&A expenses were $2.414M (down 25%).
Cash resources remain limited. Cash, cash equivalents and restricted cash were $8.069M at September 30, 2025. For the nine months, cash used in operating activities totaled $22.004M, partly offset by $11.938M of financing inflows, including February 2025 capital actions and modest ATM sales. Management states current funds are sufficient into Q1 2026 and notes substantial doubt about the ability to continue as a going concern.
On the pipeline, the Phase 2b CF study of BX004 continues in Europe, while the FDA placed a clinical hold in August 2025 related to the third‑party nebulizer device; no issues were raised regarding BX004 itself. BiomX believes it has addressed FDA device queries and expects topline results in Q1 2026. The company also reported positive Phase 2 results in DFO (BX211) and plans to advance BX011 in DFI subject to resources. Shares outstanding were 29,006,165 as of November 11, 2025.
BiomX Inc. (PHGE) reported continuing clinical progress alongside notable financing activity but disclosed material financing pressure. The company held $15.19 million in total cash and restricted cash at June 30, 2025 (amounts presented in USD in thousands) and recorded a net loss of $13.7 million for the six months ended June 30, 2025. Operating cash used was $14.82 million for the six-month period, and accumulated deficit totaled $194.39 million, raising substantial doubt about the company’s ability to continue as a going concern.
On the clinical front, BiomX reported positive Phase 2 results for BX211 in diabetic foot osteomyelitis with a statistically significant percent area reduction of ulcers (p = 0.046 at week 12) and other favorable secondary trends. BX004 (CF) advanced into a randomized Phase 2b with first patient dosed July 14, 2025, and holds FDA Fast Track and Orphan Drug designations. The company completed equity and warrant financings in 2024–2025 and recorded gross proceeds from the February 2025 SPA of $5,527 and related financings and warrant exercises that provided cash in the period, but management states current funds are not sufficient to fund operations for at least one year without additional financing.